Summary
The efficacy and side effects of the new vasodilator carprazidil and the established vasodilator minoxidil were compared in 18 hypertensive patients inadequately controlled by 2 to 4 conventional drugs; the latter included diuretics, beta-blockers and/or sympatholytics and, in half the cases, vasodilators, such as hydralazine, diazoxide or the postsynaptic alpha-blocker prazosin. The vasodilators were withdrawn and, using a crossover design all patients received carprazidil (mean final dose 88 mg) and minoxidil (20 mg) for an average period of 5 to 6 months. The effects of the 2 agents appeared to be qualitatively and quantitatively similar. Both tended to cause sodium retention and an increase in heart rate, which required an increased dose of diuretic in one third of the cases or of a beta-blocker in a quarter. With this approach mean body weight and blood volume were not altered in the established phase of carprazidil or minoxidil treatment; heart rate and plasma norepinephrine tended to be only minimally increased, plasma renin was slightly increased, and plasma aldosterone and epinephrine were largely unchanged. Supine and upright blood pressure were reduced from initial values of 189/113 and 167/113 mm Hg, to 149/95 and 138/95 mm Hg (−18 and −17%), respectively, during carprazidil, and to 154/95 and 141/96 mm Hg (−17 and −15%) during minoxidil therapy. Hypertrichosis occurred with both agents in almost all patients, and limits their more prolonged use in females. No adverse side effects on haematological parameters, liver or renal function were observed, nor was antinuclear antibody detected. It is concluded that carprazidil and minoxidil are equivalent vasodilator agents in the treatment of severe hypertension, particularly in males.
Similar content being viewed by others
References
Weidmann P (1981) Neuere blutdrucksenkende Medikamente. Schweiz Med Wochenschr 111: 625–637
Ferguson RK, Turini GA, Brunner HR, Gavras H (1977) A specific orally active inhibitor of angiotensin-converting enzyme in man. Lancet 1: 775–778
Keusch GW, Weidmann P, Campese V, Lee DBN, Upham AT, Massry SG (1978) Minoxidil therapy in refractory hypertension. Analysis of 155 cases. Nephron 21: 1–5
Mitchell HC, Pettinger WA (1978) Long-term treatment of refractory hypertension with Minoxidil. J Am Med Assoc 239: 2131–2138
Editorial (1980) Captopril: benefits and risks in severe hypertension. Lancet 2: 129–130
Gerold M, Eigenmann R, Hefti F, Daum A, Haeusler G (1981) Cardiovascular effects of a novel vasoactive antihypertensive agent, Ro 12-4713. J Pharmacol Exp Ther 216: 624–633
Grimm M, Weidmann P, Meier A, Schiffl H, Ziegler WH, Reubi FC (1981) Acute effects of a new vasodilator, Ro 12-4713, on blood pressure, plasma renin activity, aldosterone and catecholamine levels, and renal function in hypertensive and normal subjects. Eur J Clin Pharmacol 20: 169–177
Grimm M, Weidmann P, Meier A, Schiffl H, Ziegler WH (1981) Chronic treatment with the new potent vasodilator Ro 12-4713 in moderate to severe hypertension: effects on blood pressure, endocrine function, sodium and plasma volume. Eur J Clin Pharmacol 20: 79–84
Chu D, Cocco G, Strozzi C, Vallini R, Nonato M, Amerin R (1981) Antihypertensive effects of a novel peripheral vasodilator, Ro 12-4713. Eur J Clin Pharmacol 19: 233–238
Amann FW, Conen D, Bühler FR, Dubach UC (1980) Efficacy and tolerability of the new long-acting vasodilator Ro 12-4713 in severe hypertensive patients. Proc 7th Int Soc Hypertension, New Orlears, USA, May 11–14, p 4
Weidmann P (1981) Rationale Diagnostik bei Hypertonie. Ther Umsch 38 [Suppl]: 2–16
National diabetes data group (1979) Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28: 1039–1057
Weidmann P, De Châtel R, Schiffmann A, Bachmann E, Beretta-Piccoli C, Ziegler WH, Vetter W, Reubi FC (1977) Interrelations among age and plasma renin, aldosterone and cortisol, urinary catecholamines and the body sodium/volume state in normal man. Klin Wochenschr 55: 725–733
Weidmann P, Beretta-Piccoli C, Ziegler WH, Keusch G, Glück Z (1978) Age versus urinary sodium for judging renin, aldosterone and catecholamine levels. Studies in normal subjects and patients with essential hypertension. Kidney Int 14: 619–628
Kirkendall WK, Feinleib M, Freis ED, Mark AL (1980) Recommandations for human blood pressure determination by sphygmomanometer. Circulation 62: 1146A-1155A
Sealey JE, Gerten-Banes J, Laragh JH (1972) The renin system: variations in man measured by radioimmunoassay. Kidney Int 1: 240–253
Vetter W, Vetter H, Siegenthaler W (1973) Radioimmunoassay for aldosterone without chromatography: II. Determination of plasma aldosterone. Acta Endocrinol 74: 558–567
Da Prada M, Zürcher G (1976) Simultaneous radioenzymatic determination of plasma and tissue adrenaline, noradrenaline and dopamine within the fentomole range. Life Sci 19: 1161–1174
Wallenstein S, Zucker CL, Fleiss JL (1950) Some statistical methods useful in circulation research. Circ Res 47: 1–9
Meier A, Weidmann P, Ziegler WH (1981) Catecholamines, renin, aldosterone, and blood volume during chronic minoxidil therapy. Klin Wochenschr 59: 1231–1236
O'Malley K, Velasco M, Wells J, McNay JL (1975) Control plasma renin activity and changes in sympathetic tone as determinant of minoxidil-induced increase in plasma renin activity. J Clin Invest 55: 230–235
Pettinger WA, Mitchell HC (1975) Renin release, saralasin and the vasodilator-betablocker drug interaction in man. N Engl J Med 292: 1214–1217
Grim CE, Luft FC, Grim CM, Klotman PE, Van Huysse JW, Weinberger MH (1979) Rapid blood pressure control with minoxidil. Acute and chronic effects on blood pressure, sodium excretion, and the renin-aldosterone system. Arch Intern Med 139: 529–533
Pratt JH, Grim CE, Parkinson CA (1979) Minoxidil increases aldosterone metabolic clearance in hypertensive patients. J Clin Endocrinol Metab 49: 834–837
Beretta-Piccoli C, Weidmann P, De Châtel R, Reubi FC (1977) Beziehungen zwischen Blutdruck, Blutvolumen und Plasmarenin während Diuretika-Therapie bei essentieller Hypertonie: Vergleich des Mineralocorticoid-Antagonisten Spironolacton mit dem “Schleifendiuretikum” Mefrusid. Schweiz Med Wochenschr 107: 104–115
Bühler FR, Burkart F, Lütold BE, Küng M, Marbet G, Pfisterer M (1975) Antihypertensive beta blocking action as related to renin and age: a pharmacological tool to identify pathogenic mechanisms in essential hypertension. Am J Cardiol 36: 653–669
Weidmann P, Beretta-Piccoli C, Ziegler WH, Hirsch D, Reubi FC (1976) Interrelations between blood pressure, blood volume, plasma renin and urinary catecholamines during betablockade in essential hypertension. Klin Wochenschr 54: 765–773
Campese VM (1981) Minoxidil: a review of its pharmacological properties and therapeutic efficacy. Drugs 22: 257–278
Meier A, Weidmann P, Glück Z, Keusch G, Grimm M, Minder I, Reubi FC (1980) Vergleich von oralem Diazoxid und Minoxidil bei therapieresistenter Hypertonie. Klin Wochenschr 58: 681–687
Burton JL, Schutt WH, Caldwell IW (1975) Hypertrichosis due to diazoxide. Br J Dermatol 93: 707–711
Earhart RN, Ball J, Nuss DD, Aeling JL (1977) Minoxidil induced hypertrichosis: Treatment with calcium thioglycate depilatory. South Med J 70: 442–445
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bianchetti, M.G., Weidmann, P., Boehringer, K. et al. Comparative evaluation of the new vasodilator carprazidil and minoxidil in the treatment of moderate to severe hypertension. Eur J Clin Pharmacol 23, 483–489 (1982). https://doi.org/10.1007/BF00637493
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00637493